DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $73,348,036 | -10.2% | 295,639 | -13.1% | 0.30% | -13.5% |
| Q2 2023 | $81,662,640 | +0.6% | 340,261 | +5.6% | 0.34% | -5.3% |
| Q1 2023 | $81,192,669 | +96750.5% | 322,142 | +2.0% | 0.36% | -7.7% |
| Q4 2022 | $83,833 | +15.0% | 315,853 | +11.9% | 0.39% | +10.8% |
| Q3 2022 | $72,893 | -99.9% | 282,215 | +3.4% | 0.35% | +10.0% |
| Q2 2022 | $69,206,000 | -11.4% | 272,981 | +2.5% | 0.32% | +6.6% |
| Q1 2022 | $78,125,000 | -5.8% | 266,338 | +5.7% | 0.30% | -1.3% |
| Q4 2021 | $82,939,000 | +4.7% | 252,085 | -3.2% | 0.30% | -1.6% |
| Q3 2021 | $79,248,000 | -27.9% | 260,303 | -36.5% | 0.31% | -26.0% |
| Q2 2021 | $109,944,000 | +13.5% | 409,691 | -4.8% | 0.42% | +6.1% |
| Q1 2021 | $96,843,000 | +42.3% | 430,260 | +40.4% | 0.40% | +36.7% |
| Q4 2020 | $68,056,000 | +60.3% | 306,362 | +55.4% | 0.29% | +46.7% |
| Q3 2020 | $42,449,000 | +85.5% | 197,135 | +52.4% | 0.20% | +75.9% |
| Q2 2020 | $22,878,000 | -15.1% | 129,376 | -33.5% | 0.11% | -26.3% |
| Q1 2020 | $26,939,000 | -57.9% | 194,631 | -53.3% | 0.15% | -46.1% |
| Q4 2019 | $63,920,000 | +4.5% | 416,470 | -1.6% | 0.28% | -0.4% |
| Q3 2019 | $61,148,000 | +31.6% | 423,376 | +30.2% | 0.28% | +23.6% |
| Q2 2019 | $46,464,000 | +123.9% | 325,105 | +106.8% | 0.23% | +124.5% |
| Q1 2019 | $20,755,000 | +25.9% | 157,212 | -1.6% | 0.10% | +13.3% |
| Q4 2018 | $16,483,000 | -31.6% | 159,839 | -27.9% | 0.09% | -23.1% |
| Q3 2018 | $24,086,000 | -18.9% | 221,660 | -26.4% | 0.12% | -22.0% |
| Q2 2018 | $29,703,000 | -28.0% | 301,002 | -28.6% | 0.15% | -28.9% |
| Q1 2018 | $41,271,000 | +83.0% | 421,522 | +73.5% | 0.21% | +108.9% |
| Q4 2017 | $22,553,000 | -38.0% | 242,972 | -42.7% | 0.10% | -45.4% |
| Q3 2017 | $36,372,000 | -1.1% | 424,019 | -2.7% | 0.18% | +5.1% |
| Q2 2017 | $36,786,000 | -3.7% | 435,896 | -2.4% | 0.18% | -2.2% |
| Q1 2017 | $38,186,000 | -4.7% | 446,462 | -13.3% | 0.18% | -15.1% |
| Q4 2016 | $40,076,000 | +12.8% | 514,852 | +13.6% | 0.21% | +24.0% |
| Q3 2016 | $35,526,000 | +116.1% | 453,201 | +178.4% | 0.17% | +106.0% |
| Q2 2016 | $16,441,000 | -34.2% | 162,785 | -38.2% | 0.08% | -42.4% |
| Q1 2016 | $24,989,000 | -48.9% | 263,428 | -49.9% | 0.14% | -50.2% |
| Q4 2015 | $48,868,000 | +2.4% | 526,138 | -6.1% | 0.29% | -1.7% |
| Q3 2015 | $47,732,000 | +29.0% | 560,165 | +29.6% | 0.29% | +44.8% |
| Q2 2015 | $37,005,000 | -43.3% | 432,348 | -43.7% | 0.20% | -41.7% |
| Q1 2015 | $65,210,000 | +48.7% | 768,083 | +50.1% | 0.35% | +48.7% |
| Q4 2014 | $43,867,000 | +31.5% | 511,806 | +16.6% | 0.23% | +23.2% |
| Q3 2014 | $33,349,000 | +151.0% | 438,906 | +160.1% | 0.19% | +153.3% |
| Q2 2014 | $13,284,000 | -0.1% | 168,731 | -4.8% | 0.08% | -3.8% |
| Q1 2014 | $13,298,000 | -77.3% | 177,300 | -76.6% | 0.08% | -76.8% |
| Q4 2013 | $58,556,000 | +7.2% | 758,500 | -3.8% | 0.34% | +1.2% |
| Q3 2013 | $54,638,000 | – | 788,200 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |